The Newsroom
Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.
Press Release
Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced promising preclinical results for its systemic RTNova platform. The platform has successfully delivered transient gene therapy payloads to targeted tumors. Additionally, Calidi's tumor-specific virotherapy has demonstrated efficacy in killing over 60 different tumor cell lines.

Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
March 10, 2025
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital
February 24, 2025
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
January 29, 2025
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
January 28, 2025
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025
January 13, 2025
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
January 10, 2025
Discover More
Discover More
Discover More
Press Release
Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
March 10, 2025
Discover More
Press Release
Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital
February 24, 2025
Discover More
Press Release
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
January 29, 2025
Discover More
Press Release
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
January 28, 2025
Discover More
Press Release
Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025
January 13, 2025
Discover More
Press Release
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
January 10, 2025
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova
Annual Meeting – SITC 2023 – Nov 1st to 5th 2023 in San Diego, CA, USA.
November 3, 2023
Discover More
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova
Development of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic Virotherapy
December 13, 2022
Discover More
Discover More
Publication
event
NeuroNova (NNV)
NeuroNova (NNV)
NeuroNova
Supernova
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial
August 22, 2021
Discover More
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova
Abstract 6542: CAL1 vaccinia virus as oncolytic agent and potential use of cell-based platform to enhance its therapeutic effects
August 15, 2020
Discover More
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova
Abstract 4473: Evaluation of the potential of oncolytic vaccinia virus delivered by autologous SVF to modulate innate and adaptive immunity in patients with diverse solid and hematological malignancies
August 15, 2020
Discover More
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova
Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms.
May 25, 2020
Discover More
Discover More
Media
Scientific Advisory Board Member Interview - Santosh Kesari, M.D./Ph.D.
February 3, 2024
Discover More
Media
Scientific Advisory Board Member Interview - Bernard Fox, Ph.D.
February 3, 2024
Discover More
Media
Scientific Advisory Board Member Interview - W.K. Alfred Yung, M.D.
February 3, 2024
Discover More
Media
Scientific Advisory Board Member Interview - Ashok Srivastava, M.D./Ph.D.
February 3, 2024
Discover More
Media
Big Biz TV - Stephen Thesing
December 4, 2023
Discover More
Media
Big Biz TV - Allan Camaisa
December 4, 2023
Discover More
In The News
Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player
October 9, 2023
Discover More
Discover More
In The News
Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market
October 9, 2023
Discover More
Discover More